Praveen Tipirneni, MD, MBA currently serves as President and Chief Executive Officer, Morphic Therapeutic.
Previously, he was Senior Vice President, Corporate Development and Global Strategy at Cubist Pharmaceuticals from 2002 until the ~$10 billion acquisition by Merck in 2015. In his time at Cubist, he has served in the Clinical group working on the Cubicin NDA (skin and skin structure infections) and sNDA (Staph. Bacteremia and Endocarditis) teams. He has been head of Business Development since January 2006. Prior to joining Cubist, Dr. Tipirneni worked at Sun Microsystems in Corporate Strategy, Covad Communications in Corporate Strategy, and Deltagen, in Business Development and also served time as 1st Lieutenant in the U.S. Army. Dr. Tipirneni received a bachelor’s degree from MIT in Mechanical Engineering, an M.D. from McGill University. After completing his post-graduate residency in Internal Medicine at University of Illinois, Chicago, he received his MBA from the University of Pennsylvania’s Wharton School of Business in healthcare finance.